Welcome to LookChem.com Sign In|Join Free
The company logo of Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Free supplier Enterprise Certification

Free
supplier
8th
years

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Business Type:Lab/Research institutions

Audited Supplier

Main Products:
Year Established:
2017
Home>>Products>>Icotinib hydrochloride

Products Categories

Product Certification&
Enterprise Certification

More Detail

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Country: China (Mainland)

Business Type:Lab/Research institutions

Icotinib hydrochloride

CAS NO.1204313-51-8

  • Min.Order: 10 Milligram
  • Payment Terms:
Contact Supplier

Product Details

Keywords

  • Icotinib hydrochloride
  • BPI-2009H hydrochloride
  • Icotinib HCl

Quick Details

  • ProName: Icotinib hydrochloride
  • CasNo: 1204313-51-8
  • Molecular Formula: C22H22ClN3O4
  • Appearance: white powder
  • Application: For laboratory use only- not intended ...
  • ProductionCapacity: 1 Kilogram/Day
  • Purity: ≥98%
  • Storage: room temperature
  • Transportation: by air
  • LimitNum: 10 Milligram

Superiority

We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.

We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.

We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.

We make our efforts to offer customer innovative, customized, high-quality service.

Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.

 

 

 

Details

Icotinib Hcl(BPI-2009H) is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). IC50 value: 5 nM Target: EGFR and EGFR mutants in vitro: Icotinib inhibits EGFR activity in a dose-dependent manner, with an IC50 value of 5 nM and complete inhibition at 62.5 nM. Icotinib selectively solely inhibits the EGFR members including the wild type and mutants with inhibition efficacies of 61-99%. Icotinib blocks EGFR-mediated intracellular tyrosine phosphorylation in human epidermoid carcinoma A431 cells in a dose-dependent manner. Meanwhile, in our proliferation assay performed on A431, BGC-823, A549, H460, HCT8, KB and Bel-7402 cell lines, we found that the relative sensitivity of cell lines to Icotinib is A431 > BGC-823 > A549 > H460 > KB > HCT8 and Bel-7402. Icotinib exhibits a broad spectrum of antitumor activity and it is especially effective against tumors expressing higher levels of EGFR [1]. in vivo: In vivo studies demonstrated that Icotinib exhibited potent dose-dependent antitumor effects in nude mice carrying a variety of human tumor-derived xenografts. The drug was well tolerated at doses up to 120 mg/kg/day in mice without mortality or significant body weight loss during the treatment. A head to head randomized, double blind phase III trial using Gefitinib as an active control for patients with advanced non-small cell lung cancer (NSCLC) was finished recently (Trial registration ID: NCT01040780)

Hot Product